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ABSTRACT:
Cancer-associated fibroblasts (CAFs), represent a pivotal compartment of solid cancers 
(desmoplasia), and are causatively implicated in cancer development and progression. 
CAFs are recruited by growth factors secreted by cancer cells and they present a 
myofibroblastic phenotype, similar to the one obtained by resident fibroblasts during 
wound healing. Paracrine signaling between cancer cells and CAFs results in a unique 
protein expression profile in areas of desmoplastic reaction, which is speculated to 
drive metastasis. In an attempt to decipher large-scale proteomic profiles of the 
cancer invasive margins, we developed an in vitro coculture model system, based on 
tumor-host cell interactions between colon cancer cells and CAFs. Proteomic analysis 
of conditioned media derived from these cocultures coupled to mass spectrometry 
and bioinformatic analysis was performed to uncover myofibroblastic signatures of 
the cancer invasion front. Our analysis resulted in the identification and generation 
of a desmoplastic protein dataset (DPD), consisting of 152 candidate proteins of 
desmoplasia. By using monoculture exclusion datasets, a secretome algorithm and 
gene-expression meta-analysis in DPD, we specified a 22-protein “myofibroblastic 
signature” with putative importance in the regulation of colorectal cancer metastasis. 
Of these proteins, we investigated collagen type XII by immunohistochemistry, a 
fibril-associated collagen with interrupted triple helices (FACIT), whose expression 
has not been reported in desmoplastic lesions in any type of cancer. Collagen type 
XII was highly expressed in desmoplastic stroma by and around alpha-smooth 
muscle actin (α-SMA) positive CAFs, as well as in cancer cells lining the invasion 
front, in a small cohort of colon cancer patients. Other stromal markers, such as 
collagen type III, were also expressed in stromal collagen, but not in cancer cells. In a 
complementary fashion, gene expression meta-analysis revealed that COL12A1 is also 
an upregulated gene in colorectal cancer. Our proteomic analysis identified previously 
documented markers of tumor invasion fronts and our DPD could serve as a pool for 
future investigation of the tumor microenvironment. Collagen type XII is a novel 
candidate marker of myofibroblasts, and/or cancer cells undergoing dedifferentiation.Oncotarget 2012; 3:  267-285 268 www.impactjournals.com/oncotarget
ABBREVIATIONS
CAF, cancer-associated fibroblast
CDCHO, chemically defined Chinese hamster ovary
CK, cytokeratin
CM, conditioned media
CRC, colorectal cancer
DDT, dichloro-diphenyl-trichloroethane
DMEM, Dulbecco’s modified Eagle medium
DPD, desmoplastic protein dataset
ECM, extracellular matrix
EMT, epithelial-to-mesenchymal transition
ESI, electrospray ionization
FACIT, fibril-associated collagen with interrupted triple helices
FBS, fetal bovine serum
5-FU, 5-fluororacil
HGF, hepatocyte growth factor
HPLC, high-performance liquid chromatography
ICC, immunocytochemistry
IGF, insulin growth factor
IHC, immunohistochemistry
IL, interleukin
KLK, kallikrein-related peptidase
MEM, minimum essential medium
MMP, matrix metalloproteinase
MS/MS, tandem mass spectrometry
NF, normal fibroblast
PBS, phosphate buffered saline
RPLC, reverse-phase liquid chromatography
SCX, strong cation exchange
SMA, smooth muscle actin
TGF, transforming growth factor
TNF, tumor necrosis factor
uPA, urokinase-type plasminogen activator
VEGF, vascular endothelial growth factor
INTRODUCTION
The  “cancer/tumor  invasion  front”  represents  a 
spatially-organized tumor site, where many aspects of 
cancer development and progression are regulated at the 
single- and collective-cell levels. The cancer invasion 
front is, in fact, the invasive margins of any primary 
neoplasm that has breached the basement membrane at 
an earlier point, and is currently excavating a metastatic 
pathway through the normal underlying stroma, towards 
the lymphatic or blood vessels [1, 2]. Paracrine signaling 
between cancer cells and associated stromal cells is almost 
exclusively present at the invasive sites. Cancer cells tend 
to deploy a cell-biological program, called epithelial-to-
mesenchymal transition (EMT) [3, 4], during which, they 
lose epithelial shape, polarity and cytoskeletal organization 
and gain mesenchymal-like properties. These changes are 
followed by large-scale alterations in their gene expression 
machinery [3, 5]. EMT, has been considered for a long 
time as an important trait of metastasizing cells [4]. Cancer 
cells undergoing EMT detach from the main cancerous 
core, and obtain a highly-malignant phenotype; this cancer 
cell subpopulation has been described as “tumor bud” and 
Figure 1: Experimental outline for identification, characterization and validation of desmoplastic proteomic signatures 
in CRC. Nodes in bold represent the experimental steps, while the remaining nodes describe strategies and tools. See also non-standard 
abbreviations for abbreviated terms.Oncotarget 2012; 3:  267-285 269 www.impactjournals.com/oncotarget
is now histopathologically evaluated and linked to poor 
prognosis and patient survival [6]. 
The cancer-associated stroma is a highly important 
constituent of the cancer invasion front, in many cases 
consisting of cancer-associated fibroblasts (CAFs). The 
accumulation of CAFs peritumorally represents the host 
response to the presence of neoplastic lesions within the 
stroma. CAFs are normal host cells, particularly derived 
by normal quiescent fibroblasts (NFs), although other 
sources have been also reported (e.g. mesenchymal stem 
cells, bone marrow-derived stem cells, endothelial cells), 
which have deployed a specific cell-biological program, 
termed  “myofibroblastic  differentiation”  [7,  8].  These 
peritumoral myofibroblasts are characterized by altered 
Figure 2: Coculture development. (A) Cell proliferation assay (Alamar Blue). SW480 and SW620 colon cancer cell lines were treated 
with 18Co fibroblast CM or left untreated (placebo) and cell proliferation was measured in a time-dependent manner. Note that 18Co CM-
stimulated cancer cells proliferate faster than placebo-treated ones. * denotes statistical significance (p<0.05, t-test). (B) Cell migration 
(scratch) assay. SW480 and SW620 colon cancer cell lines were seeded in monolayer, scratched and treated with 18Co fibroblast CM or 
left untreated (placebo). Note that 18Co CM-stimulated cancer cells heal the in-vitro wound faster. (C) Resistance to chemotherapy assay. 
SW480 and SW620 colon cancer cell lines were treated with 18Co fibroblast CM or left untreated (placebo), following treatment with 
increasing doses of 5-FU. Note that 18Co CM caused pharmacological rescue in 5-FU-treated SW620 cells, while no significant effect 
was shown for SW480 cells. * denotes statistical significance (p<0.05, t-test). (D) Cell adhesion assay. SW480 and SW620 cells were 
suspended in serum-free CM and plated either in CDCHO, or treated with increasing doses of 18Co fibroblast CM, or on top of pre-seeded 
fibroblasts, and adhesion was evaluated with microscopy. Note that cancer cells form spheroids and loosely attach to the plates only with 
preseeded 18Co cells or treated with 18Co CM. (E) MMP2 and uPA ELISA in CM from mono- or co-cultures. Note increased secretion 
of both proteins in cocultures. (F) α-SMA ICC. Note that, in contrast to monocultures, 18Co cells in coculture conditions express α-SMA. 
Cancer cells are negative for α-SMA. All magnifications x10, except third and fifth figure (x40).Oncotarget 2012; 3:  267-285 270 www.impactjournals.com/oncotarget
proliferative, migratory and contractile behavior compared 
to NFs. In addition, they fully deploy smooth-muscle-like 
gene and protein expression machinery, which has been 
initially noticed in stromal responses in tissue wounding 
[9]. For instance, CAFs initiate the expression of alpha-
smooth muscle actin (α-SMA), which is speculated to 
provide smooth muscle-like contractile activity, and is the 
most significant hallmark to distinguish CAFs from NFs 
[10].
It is now clear that CAFs constitute a rich source 
of matrix remodeling molecules (e.g. tenascin-C, matrix 
metalloproteinases) that directly or indirectly affect the 
metastatic cascade and are responsible for the increased 
deposition of extracellular matrix (ECM) components at 
the tumor invasion front, a type of lesion that has been 
described as “desmoplasia” [7, 9, 11-14]. In addition, 
CAFs produce multiple growth factors [e.g. insulin growth 
factor (IGF), hepatocyte growth factor (HGF)], which 
promote tumor cell proliferation, survival and motility/
migration [10, 15]. Moreover, CAFs participate in yet 
other paracrine signaling pathways that together regulate 
and promote inflammation [e.g. interleukin-1β (IL-1β), 
tumor necrosis factor-α (TNF-α)] [16], and angiogenesis 
[e.g. vascular endothelial growth factor (VEGF)] [17], 
which  further  qualifies  them  as  central  mediators  of 
various aspects of carcinogenesis. Overall, CAFs seem 
to serve as a pivotal source of strategies, deployed at 
both primary and metastatic tumor sites, mediating and 
supporting the malignant properties of cancer spreading 
[18, 19].
Currently,  high-throughput  studies,  mostly 
genome-wide-  and  proteome-based,  are  deployed  for 
Gene Name Protein Name Affymetrix Probe
Myofibroblastic
Signature
Fetal-like 
Signature
ASPH
Aspartyl/asparaginyl beta-
hydroxylase
209135_at yes no
CD99 Isoform I of CD99 antigen 201029_s_at yes no
CDH11 Cadherin-11 239769_at yes yes
CDH2 Cadherin-2 203440_at yes no
COL12A1
Isoform 4 of Collagen alpha-1(XII) 
chain
225664_at yes yes
COL4A1
Isoform 1 of Collagen alpha-1(IV) 
chain
211980_at yes yes
CRTAP Cartilage-associated protein 201380_at yes no
EXT2 Isoform 1 of Exostosin-2 202013_s_at yes no
GALNT10
Isoform 1 of Polypeptide N-
acetylgalactosaminyltransferase 10
212256_at yes no
GREM1 Isoform 1 of Gremlin-1 218468_at yes no
IL6ST
Isoform 1 of Interleukin-6 receptor 
subunit beta
212195_at yes no
ITGA5 Integrin alpha-5 201389_at yes yes
LAMB1 LAMB1 200 kDa protein 201505_at yes yes
LEPRE1 Isoform 3 of Prolyl 3-hydroxylase 1 220750_s_at yes no
LOX Protein-lysine 6-oxidase 215446_s_at yes yes
MXRA8
Isoform 2 of Matrix-remodeling-
associated protein 8
213422_s_at yes yes
NID2 Nidogen-2 204114_at yes yes
PAPPA Pappalysin-1 224941_at yes no
PROCR
Endothelial protein C receptor 
precursor
203650_at yes yes
SRPX2
Sushi repeat-containing protein 
SRPX2
205499_at yes no
TPD52L2 Isoform 2 of Tumor protein D54 201379_s_at yes no
VCAN Isoform V0 of Versican core protein 221731_x_at yes yes
Table 1Oncotarget 2012; 3:  267-285 271 www.impactjournals.com/oncotarget
the  scrutinization  and  subsequent  investigation  of  the 
tumor microenvironment [20-22]. Emerging novel mass 
spectrometry-based proteomic strategies have allowed for 
simultaneous identification and quantification of thousands 
of proteins, even in complex biological mixtures [23]. 
Hence, proteomic platforms have been widely developed 
to  provide  insight,  especially  into  the  rationalized 
biomarker discovery field, and to additionally provide 
more systematic understanding of various physiological 
and pathophysiological, cellular processes [24, 25]. In this 
study, we attempted to decipher and characterize molecular 
events of tumor-host cell interactions that occur early 
in the course of metastasis, using the colorectal cancer 
desmoplastic microenvironment as a model system. In 
this approach, we generated in vitro cell-contact cocultures 
of colorectal cancer (CRC) cell lines and colonic NFs, 
in an attempt to mimic the paracrine signaling milieu 
of colorectal cancer tumor invasion fronts. Following a 
previously-described  proteomic  strategy  [24,  26],  we 
subjected these cocultures to comprehensive secretome 
analysis  using  liquid  chromatography-tandem  mass 
spectrometry  (LC-MS/MS),  and  generated  a  pool  of 
potential candidates that could be liberated at the tumor 
invasion  front  and  regulate  various  aspects  of  cancer 
metastasis. This strategy successfully integrates an in vitro 
coculture model system with proteomics, bioinformatics 
and tissue wide-based expressional studies.
RESULTS
Development of a desmoplastic coculture model 
system
We tested our strategy (Figure 1), with a “colorectal 
cancer-colonic  fibroblast”  tumor-host  cell  interaction 
model  system,  for  the  following  reasons:  (A)  The 
contribution of CAFs in the early course of most solid 
cancers is now well-recognized [19]. (B) Desmoplasia 
has  been  thoroughly  investigated  and  associated  with 
progression  of  gastrointestinal  cancers,  especially  in 
pancreatic and colorectal cancers [27, 28]. (C) A normal 
colonic  fibroblast  cell  line  (18Co)  was  commercially 
Figure 3: Secretome analysis. Proteomic analysis of mono-culture and coculture CM. Venn diagrams show reproducibility among 
triplicates. In squares are the numbers of identified proteins with a minimum of two peptide hits. Monocultures are depicted with red and 
cocultures with blue color. The monoculture datasets have been used as exclusion lists to the coculture ones, identifying a dataset of 286 
coculture-specific proteins (depicted with an asterisk).Oncotarget 2012; 3:  267-285 272 www.impactjournals.com/oncotarget
available and these cells could be cultured and co-cultured 
very easily, compared to other types of stromal cells (e.g. 
endothelial cells, immune cells). Thus, we established 
in vitro,  cell-contact  colorectal  cancer  cocultures 
(Supplementary Figure 1). 
Proteomic  analysis  in  only  one  coculture  would 
probably  reveal  certain  cell  line  selection  biases;  by 
selecting  at  least  two  cancer  cell  lines,  we  would  be 
able to cross-examine any potential candidates of tumor 
development and progression, via proteomic delineation of 
their secretomes. Among the plethora of colon cancer cell 
lines, we selected the SW480/SW620 as a reasonable in 
vitro system for the screening; this system would allow us 
to capture some colon cancer heterogeneity, since SW480/
SW620 cell lines were obtained from the same patient, but 
at a different tumor stage [29]. We, therefore, developed 
cell  contact,  two-dimensional  cocultures  of  SW480/
SW620 cells and 18Co normal colonic fibroblasts (named 
SW480Co and SW620Co, respectively), and used the 
relevant monocultures as controls (Supplementary Figure 
Figure 4:  Myofibroblastic signature. (A) Algorithm of smooth muscle enrichment analysis. For details see text. The algorithm retrieves 
smooth muscle-expressed and/or -specific proteins, as potential myofibroblastic markers. (B) Heat map generated from Genevestigator, 
showing the expression of the 22 protein subset of the proposed myofibroblastic signature, in various normal cell arrays. Red arrows depict 
the representative smooth muscle-like cells. Columns represent the 22-gene cluster of the myofibroblastic signature; rows represent normal 
tissues/cell types in which th gene expression of each probe was investigated. (C) Hierarchical clustering of the myofibroblastic signature 
across various age groups in Homo sapiens arrays revealed a cluster of 10 proteins, which are highly-expressed in prenatal (fetal) arrays, 
when compared to the adult ones. Columns represent the probes of the 22-gene cluster of the myofibroblastic signature; rows depict the age 
group in days. The red arrow points to the Collagen type XII (COL12A1) probe.Oncotarget 2012; 3:  267-285 273 www.impactjournals.com/oncotarget
1). Similar viable cocultures (HT29Co, HCT116Co) were 
generated with other cancer cell lines (HT29 and HCT116, 
respectively) (Supplementary Figure 1).
First, we tested whether paracrine signaling between 
these colon cancer cell lines and 18Co normal colonic 
fibroblasts could occur, under various in vitro coculture 
setups.  To  verify  this,  we  collected  CM  from  2-day 
monocultures of 18Co NFs and stimulated the SW480/
SW620 cells, to investigate whether they could utilize 
paracrine factors derived from stromal cells. Both SW480 
and SW620 colon cancer cell lines displayed statistically 
significant increases in their growth rate (p<0.05), in a 
time-dependent  cell  proliferation  assay,  when  treated 
with 18Co CM (Figure 2A). This observation was in 
concordance with cell scratch assays; SW480 and SW620 
cells treated with 18Co CM were able to heal the in vitro 
wound  faster  than  the  placebo-treated  cells,  an  effect 
that points to enhanced regulation of cell proliferation 
and perhaps migration (Figure 2B). Next, we performed 
an in vitro resistance-to-chemotherapy assay, measuring 
cell viability with the Alamar Blue assay. In this assay, 
when SW480 cells were treated with 5-FU, a well-known 
drug used in the FOLFOX adjuvant chemotherapy for 
colorectal  cancer  treatment  [30],  no  pharmacological 
rescue  was  noticed  with  the  parallel  administration 
of 18Co CM (p>0.05). However, 18Co CM caused a 
significant rescue in the 5-FU-treated SW620 cells, in a 
dose-dependent manner (p<0.05) (Figure 2C). This could 
potentially suggest that SW620 cells might utilize survival 
factors present in the 18Co CM. We then, performed an in 
vitro cell adhesion assay. In this setup, SW480 and SW620 
cells were resuspended in serum-free medium and were 
subsequently seeded in tissue culture plates. The absence 
of serum proteins from the CM did not allow these cells 
to adhere to the plates two days after the initiation of 
the assay (Figure 2D). However, when these cells were 
supplemented with increasing doses of 18Co CM (10% 
or 50%), they formed spheroids with loose attachment on 
the plates, in a dose-dependent manner (Figure 2D). In 
concordance with this, when SW480 or SW620 cells were 
seeded on top of 10% confluent pre-seeded 18Co cells, 
without stimulation by 18Co CM, some cells managed 
to  adhere  onto  or  away  from  the  fibroblasts  (Figure 
2D). Overall, these phenotypic observations support the 
notion that SW480/SW620 cells are capable of utilizing 
paracrine signals from stromal cells and stimulate various 
biological processes, such as growth, migration, adhesion 
and survival.
Before subjecting CM to proteomic analyses, we also 
wished to test whether paracrine signaling between cancer 
cells and 18Co NFs could lead to the transdifferentiation 
of the latter cells into CAFs, an observation that would 
be in agreement with the literature [8], and would render 
our rationale more concrete. To evaluate such processes, 
we measured MMP2 and uPA, two prominent markers 
of CAFs [9], in mono- and coculture CM, using specific 
immunoassays. These two factors were not secreted by 
any of the two colon cancer cell lines, but low levels were 
detected in the 18Co monocultures (Figure 2E). However, 
their secretion was significantly increased (p<0.05) in 
both SW480Co and SW620Co cocultures (Figure 2E). 
The exact origin of MMP2 and uPA in the cocultures 
was not defined. These could be secreted by CAFs, or 
the cancer cells in response to CAF signals [for instance, 
cancer cells undergoing EMT [6]]. Literature suggests that 
these factors are stromatogenic, and are most probably 
Figure 5: Immunohistochemical markers defining the cell populations of the tumor invasion front. Tumor invasion front 
area (red arrows) of colorectal carcinoma (black arrows) with myofibroblastic stromal reaction (green arrows) containing tumor budding 
cells (blue arrows). (A & D) H-E stain. (B & E) Pan-keratin immunoexpressed strongly in CRC cells and slightly in myofibroblasts. (C & 
F) alpha-SMA immunoexpressed in myofibroblastic stromal reaction. Magnifications: A, B & C x 200, D, E & F x400.Oncotarget 2012; 3:  267-285 274 www.impactjournals.com/oncotarget
secreted by CAFs [9], although other stromal cells (e.g. 
tumor-associated macrophages) have also been reported to 
secrete them [31]. These factors were also secreted by our 
two decoy cocultures HT29Co and HCT116Co but not by 
either HT29 or HCT116 monocultures (Figure 2E). 
We additionally tested the expression of α-SMA, 
an  intermediate  filament  protein  that  is  known  to  be 
expressed by smooth muscle and other smooth muscle-like 
cells (i.e. myofibroblasts), but not reported to be expressed 
by NFs [7, 9]. Although some groups have reported that in 
vitro cultured NFs might express small amounts of α-SMA 
[32, 33], we found that α-SMA expression was higher 
in cocultured fibroblasts compared to the monocultured 
ones, while cancer cells did not express it at all, using 
ICC (Figure 2F). Together, these phenotypic observations 
demonstrate that in vitro  interactions  of  cancer  cells 
with fibroblasts, may lead to the differential expression 
of  prominent  markers  of  CAFs.  Thus,  our  proposed 
SW480Co/SW620Co coculture model could provide an 
in vitro representation of the tumor invasion front.
Comprehensive proteomic analysis of mono- and 
coculture CM
We collected CM from all mono- and cocultures, 
after a 2-day incubation period and subjected them to 
comprehensive secretome analysis, following an in-house 
protocol [26], with slight modifications (as explained in 
Methods). We used the stringent criterion of a minimum 
of  two  peptide  hits  for  protein  identification  and  all 
experiments were performed in triplicate, to increase the 
accuracy of identification. Therefore, a total of 15 CM 
samples, corresponding to five experimental conditions 
(SW480,  SW620,  18Co,  SW480Co  and  SW620Co) 
were collected, trypsin-digested and subjected to SCX-
RPLC-MS/MS. We identified 1393, 1213, 423, 1283 and 
1033 proteins for SW480, SW620, 18Co, SW480Co and 
SW620Co, respectively (Supplementary Tables 1-5), with 
acceptable reproducibility among the replicates (ranging 
from 63% to 93% in each mono- or coculture) (Figure 3). 
A total of 2142 non-redundant proteins were identified 
with the combination of all protein datasets. The complete 
lists of proteins identified (≥ 2 peptides), including number 
of  unique  peptides,  IPI  accession  number,  number  of 
assigned spectra and % sequence coverage is presented in 
Supplemental Tables 1-5 for each experimental condition. 
Currently, there is no other proteomic study, delineating 
the secretome of 18Co normal colonic fibroblasts and 
consequently  of  the  relevant  cocultures.  However,  in 
previous studies, the secretomes of SW480 and SW620 
cell lines have been deciphered through various proteomic 
approaches  [34-36].  Identification  of  proteins  in  a 
comparative context was made in only one of these studies 
[34], in which, an LC-MS/MS approach was also used. 
In that study, 796 and 828 proteins were identified for 
SW480 and SW620 cell lines respectively, with the same 
criterion of two peptide hits for protein identification. Our 
secretomes for these two colon cancer cell lines (1293 
and  1213  proteins  for  SW480  and  SW620  cell  lines, 
respectively) are more complete.
To test the accuracy of the MS data, we considered 
a  small  panel  of  four  secreted  internal  control 
proteins, including KLK6, KLK7, KLK10 and MMP2 
and  investigated  their  expression  through  specific 
immunoassays in all CM subjected to secretome analysis, 
and  compared  their  levels  to  the  respective  spectral 
counts (independent MS/MS events) from the LC-MS/
MS  analysis  (Supplementary  Figure  2).  CM  from  all 
the mono- and cocultures were collected at days 2 and 
4 and were normalized for total protein content, before 
ELISA analysis. All internal control proteins showed an 
increase between day 2 and 4 in the cultures, where they 
were found to be secreted. Specifically, KLK6 was found 
in all but the 18Co secretome and was identified with 
more than 10 spectral counts in all replicates of SW480, 
SW620 and their cocultures. KLK7 was identified with 
3 spectral counts in the SW480 secretome; no positive 
identification  was  made  in  SW480Co  secretome. 
Accordingly, KLK7 immunoassay verified this result, as 
KLK7 was detectable in low amounts (<2.5 ug/L), only in 
the SW480 supernatant. KLK10 was measured in SW480 
and SW480Co secretomes using the specific immunoassay 
and was identified with more than 7 spectral counts in all 
replicates in the LC-MS/MS analysis. Finally, MMP2 was 
secreted in large amounts by 18Co normal fibroblasts (~40 
ug/L at day 4), and the relevant cocultures. MMP2 was 
identified with a large number of spectral counts (~25-
50) in all 18Co-containing mono- and cocultures. Thus, 
our mass spectrometry and immunoassay data suggest 
that KLKs are probably secreted by cancer cells, while 
MMP2 is mainly stromatogenic. We also demonstrated 
in vivo  relevance  of  our  internal  control  expression 
data,  using  immunohistochemistry.  KLK6,  KLK7  and 
KLK10 immunoexpression was observed in the columnar 
cells of normal colon mucosa. Goblet cells also showed 
cytoplasmic staining, while most mucin droplets remained 
unstained.  Colorectal  adenocarcinoma  cases  showed 
a variable cytoplasmic KLK immunoexpression, from 
negative to strongly positive (Supplementary Figure 3). 
Increased MMP2 expression in cancer-associated stroma 
and desmoplasia has been widely demonstrated by other 
groups [37, 38].
Generation  of  a  comprehensive  “Desmoplastic 
Protein Dataset” (DPD)
Combination  of  the  two  coculture  datasets 
(SW480Co  and  SW620Co)  gave  rise  to  1551  non-
redundant proteins (Figure 3). In an attempt to generate a 
comprehensive heterotypic dataset of secreted candidate Oncotarget 2012; 3:  267-285 275 www.impactjournals.com/oncotarget
proteins present in desmoplastic invasion fronts, we first 
used all monoculture datasets (SW480, SW620, 18Co) 
as exclusion datasets, to retain the “coculture-specific” 
proteins. This filter allowed us to generate a list of 286 
proteins  (Figure  3A,  Supplementary  Table  6),  which 
were either de novo expressed in the cocultures, or could 
be  expressed  in  monocultures  in  small  amounts,  not 
detectable via LC-MS/MS. This filter also gave rise to 591 
monoculture-specific proteins and 1265 proteins, present 
in at least one mono- and one coculture dataset, as shown 
in the Venn diagrams (Figure 3). Although these 591 
monoculture-specific proteins could also be of functional 
importance,  we  decided  to  focus  on  the  286  protein 
dataset,  since  the  latter  proteins  could  be  potentially 
present  at  high  concentrations  at  the  cancer  invasion 
front. We cannot exclude the possibility that some of these 
proteins (probably of low-abundance) were not detected 
in some monoculture CM, due to methodological and 
instrumental limitations (relatively low sensitivity). The 
three biological replicates and the 2-peptide hit criterion 
should minimize such biases. 
Secondly, we filtered the 286 protein dataset through 
the secretome algorithm (see Methods), to remove all 
intracellular  contaminants  and  focus  on  the  secreted 
proteins of the invasion front. With this filter we identified 
152  proteins  (depicted  as  “TRUE”  in  the  prediction 
column of Supplementary Table 7). Of these, 98 were 
predicted as non-membraneous and 54 as membraneous, 
spanning a number of transmembrane helices from 1 to 
10. Of the non-membraneous proteins, 75 were predicted 
as secreted with the classical secretory pathway and 23 
with the non-classical one (Supplementary Table 7). Since 
this 152-protein dataset represents a dataset of secreted 
proteins originating from tumor host cell interactions, we 
assigned it with the term “Desmoplastic Protein Dataset” 
(DPD) (Supplementary Table 8). 
Smooth muscle enrichment analysis in DPD
A consistent feature of peritumoral fibroblasts in 
desmoplastic  lesions  is  a  myofibroblastic  phenotype, 
which is based on the synthesis of intracellular smooth-
muscle  like  proteins,  in  particular  α-SMA  [39,  40]. 
Multiple other markers of myofibroblastic differentiation 
have  been  described,  most  of  which  are  components 
of  the  ECM  [9].  It  is  now  well-accepted  that  CAFs 
deploy their smooth muscle gene and protein expression 
machinery, which contributes to their enhanced capability 
of  mechano-transduction  and  migration  within  the 
tumorigenic  stroma  [9].  Thus,  we  assumed  that  the 
DPD could be possibly enriched in secreted markers of 
myofibroblastic differentiation. We created a rationalized 
gene-expression meta-analysis strategy, termed as “smooth 
muscle enrichment analysis”, to investigate such proteins. 
The meta-analysis criteria (Figure 4A) included proteins 
of the DPD that were highly expressed in smooth muscle 
(e.g. bronchial smooth muscle) or smooth muscle-like 
(e.g. hepatic myofibroblast) arrays, independent to the 
organ of origin (i.e. not necessarily in colonic tissues). 
Our results designated 22 proteins as smooth muscle-
expressed or -specific (Figure 4B, Table 1), which is a 
novel, myofibroblastic signature. In addition, there was 
a tendency for these proteins to be highly expressed in 
mesenchymal-like  arrays,  rather  than  epithelial-like, 
when assessed in the gene expression meta-analysis heat 
map  (Figure  4B).  For  instance,  bone  marrow  stromal 
Figure 6: Immunohistochemical profile of the myofibroblastic stromal reaction in areas of invasion of CRC. (A-C) 
Collagen III immunohistochemical expression in the stromal collagen and myofibroblasts (arrows) around the tumor invasion front in 
cases of CRC (D-F) Collagen XII immunohistochemical expression in the stromal collagen and myofibroblasts (arrows) around the tumor 
invasion front in the same cases of CRC, respectively, and in tumor cells of the tumor invasion front (arrowheads). Magnifications: A, D, 
F x200 and B, C, E x400.Oncotarget 2012; 3:  267-285 276 www.impactjournals.com/oncotarget
cell, chorion villus cell, endometrial stromal cell, bone 
marrow-derived  mesenchymal  cell  and  mesenchymal 
stem cell expression was significantly high for most of 
these proteins. In contrast, transcript expression of these 
candidates was particularly low in arrays corresponding to 
immune cells (monocytes, B-lymphocytes, T-lymphocytes, 
dendritic cells), bone marrow haematopoietic lineages, as 
well as epithelial-like arrays (tracheal, bronchial, lung, 
epidermal keratinocyte, tongue squamous cell). Finally, 
using  Gene  Enrichment  Profiler  (see  Methods),  we 
validated that all proteins of the myofibroblastic signature 
had very high enrichment scores in smooth muscle arrays 
(Supplementrary Figure 4).
We  further  compared  the  relative  expression  of 
these 22 proteins in various prenatal and postnatal arrays, 
allowing us to classify them into distinct clusters with 
specific gene expression patterns in fetal tissues. This 
analysis revealed a small cluster of 10 proteins (Figure 
4C red box, Table 1), which was highly expressed in fetal 
tissue arrays compared to adult ones. This could be an 
interesting observation, since it is now speculated that 
CAFs obtain two potential phenotypes at the tumor-host 
cell interface area, the myofibroblastic phenotype and 
the fetal-like phenotype [9]. Initially it was shown that 
the latter subpopulation was exclusively present during 
developmental  processes,  but  later,  it  became  evident 
that fetal-like fibroblasts participate in wound healing 
processes in adult tissues, as well [41]. Thus, fetoprotein 
cluster analysis could specify secreted, fetal-like markers 
in DPD, which could characterize the tumor invasion 
front.
Collagen  type  XII  is  as  a  novel  marker  of 
myofibroblastic  differentiation  in  colorectal 
cancer desmoplastic lesions
Of all the candidates of the myofibroblastic signature, 
we turned our focus to collagen type XII, for the following 
reasons:  (A)  Various  ECM  components  deposited  in 
desmoplastic  lesions,  including  collagens,  have  been 
widely demonstrated to be markers of myofibroblastic 
differentiation  [9].  (B)  Collagen  type  XII  has  been 
previously linked to other fibrotic diseases [42, 43], but 
never specifically to cancer-associated desmoplasia. (C) 
Data obtained from our proteomic analysis suggests that 
Figure 7: Investigation of Collagen type XII expression in colon cancer cells. (A) Cells lining the invasion front (encircled) and 
tumor budding cells (arrows) were found positive for collagen type XII and negative for collagen type III.  (B) Mean ratios of Collagens 
type III and XII, calculated from gene expression meta-analysis between colorectal cancer adenocarcinomas and normal colonic mucosa 
in a total of 6 experiments in the Genevestigator database. (C) Mean COL12A1 expression in cancerous lesions of 24 CRC patients and 
adjacent to the tumor normal colonic mucosa. All bars are mean values with standard deviations calculated from all experiments or 
replicates.Oncotarget 2012; 3:  267-285 277 www.impactjournals.com/oncotarget
it is extremely unlikely that collagen type XII could be a 
false positive protein (it was identified with a very large 
number of peptides; 68 in SW480Co and 92 in SW620Co). 
(D) Collagen type XII has been previously demonstrated 
by proteomics to be expressed by smooth muscle cells, 
mainly perivascularly. In this global proteomic approach 
[44], a mass spectrometry-based platform for identification 
of vascular extracellular proteins in human aorta samples, 
revealed a novel ECM component signature, including 
various proteoglycans and collagens (such as collagen 
type XII). (E) Finally, collagen type XII also belonged to 
the fetal-like-generated subsignature (probe 225664_at, 
Figure 4C, Table 1), thus it could be associated with the 
phenotype of fetal-like CAFs, giving additional strength 
to its prioritization. For these reasons, we investigated 
collagen type XII expression with immunohistochemistry 
in colorectal cancer desmoplastic lesions.
First,  we  defined  the  cancerous  and  stromal 
subpopulations at invasive fronts of desmoplastic lesions 
in a small cohort of CRC patients (Figure 5). In such 
areas, the stromal reaction consisted of collagen, CAFs 
and inflammatory cells (Figures 5A&D). Cancer cells 
invading the stroma were characterized by strong keratin 
expression (Figures 5B&E). A strong cytoplasmic α-SMA 
immunohistochemical  expression  was  observed  in  the 
myofibroblasts  around  CRC  invasive  areas  (Figures 
5C&F). Subsequently, we investigated collagen expression 
in these samples. Both collagen type III and XII were 
strongly co-immunoexpressed in the collagenous matrix 
around tumor cell cohorts, as well as in CAFs (Figures 
6A-E). Thus, our data strongly support the notion that 
collagen type XII could be an indicator of myofibroblastic 
induction in CRC desmoplastic lesions.
Colon cancer cells, in addition to CAFs, could 
potentially contribute to the secretion of collagen 
type XII at the desmoplastic invasion front.
One finding from our analysis was the expression of 
collagen type XII by some cancer cells at the interaction 
line (Figures 6D-F, Figure 7A), and additionally by tumor 
buds (Figure 7A). Tumor cells positioned in the core of the 
cohort were negative for collagen type XII (Figures 6D-F). 
This was not the case for collagen type III, since this type 
of collagen was characteristic of the stromal compartment, 
exclusively (Figures 6A-C, Figure 7A). Based on these 
observations, it was tempting to speculate that collagen 
type XII, in addition to being a potential myofibroblastic 
marker, it could also serve as marker of the tumor invasion 
front cancer cells. 
We  further  investigated  whether  there  was  any 
evidence  of  collagen  type  XII  expression  by  colon 
cancer  cells.  First,  by  using  gene  expression  meta-
analysis  of  cancer  microarrays  (Genevestigator),  we 
identified  six  experiments  from  two  studies  [45,  46], 
five of which depicted comparisons of gene expression 
patterns between colon cancer and normal colon mucosa 
tissues (Supplementary Figure 5). We calculated mean 
gene expression levels for the probes corresponding to 
both collagens and found that collagen type XII is ~2-
fold increased, while collagen type III expression was 
not significantly altered in colon cancer cells compared 
to normal colonic mucosa (Figure 7B, Supplementary 
Figure  5).  We  validated  the  collagen  type  XII  meta-
analysis results in a cDNA array, consisting of 24 CRC 
patients, matched with normal colonic mucosal tissue 
adjacent to the tumor (Supplementary Figure 6). This 
analysis  revealed  a  ~3.8-fold  overexpression  (p<0.05) 
of collagen type XII mRNA levels in cancerous tissue 
compared to normal colon mucosa (Figure 7C). However, 
these data should be interpreted with caution since stromal 
contamination  occurs  to  some  extent  upon  sampling 
epithelial cancers invading the stroma. Taken together, 
we provided evidence that collagen type XII might be 
produced by cancer cells at the desmoplastic invasion 
front, in addition to CAFs.
DISCUSSION
We applied a mass spectrometry-based proteomic 
strategy  to  investigate  tumor-host  cell  interactions, 
based  on  proteomic  analysis  of  mono-  and  coculture 
CM. We particularly sought to identify novel regulatory 
mechanisms of carcinogenesis in desmoplastic invasion 
fronts  of  colorectal  cancer.  Such  high-throughput 
strategies may provide new insights into the regulation of 
cancer-related phenotypes that are microenvironmentally 
determined [47]. It should be noted that our in vitro model 
system involved only two colon cancer cell lines (SW480 
and SW620), which were derived from a different stage 
of the same patient [29]. Thus, the proteins of the DPD 
(Supplementary Table 8) may have been influenced by the 
specific genetic backgrounds of these two colon cancer 
cell lines. For instance, it is known that SW480 is deficient 
in SMAD4, although it is responsive to TGF-β signaling 
[48, 49]. Therefore, the non-canonical TGF-β signaling 
in the SW480 mono- and cocultures could be partially 
responsible for the identified subproteomes. Although, the 
inclusion of many cell lines could probably resolve such 
issues, this also entails additional cost. Since our approach 
depicts a proof-of-concept study, we conclude that the 
DPD should be evaluated with caution, as it represents 
only a proteomic snapshot of the dynamic interactions of 
the tumor invasion front.
Of  considerable  importance  in  this  study,  is  the 
identification  of  the  desmoplastic protein dataset 
(Supplementary Table 8). This is the first characterization 
of  a  proteomic  dataset  that  corresponds  to  candidate 
secreted  proteins  of  the  “cancer  invasion  front”.  One 
limitation is our inability to distinguish whether a protein 
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in the coculture conditions. Since none of these proteins 
were  identified  via  mass  spectrometry  in  any  of  the 
monocultures, their presence in the coculture CM could 
be attributed to the tumor host cell interactions, such as 
paracrine  signaling  through  secreted  or  cell-adhesion 
factors. However, it is possible that many low-abundance 
proteins (e.g. cytokines) might not have been identified in 
a monoculture dataset, due to method sensitivity. Thus, the 
DPD is prone to false positives. For this reason, proteins 
that were considered as candidate regulators of tumor-
host cell interactions, were subjected to both stringent 
criteria of identification (at least 2 peptides) and validation 
analyses, including IHC.
An examination of the DPD reveals the paradoxical 
co-existence  of  positive  and  negative  regulators 
of  carcinogenesis.  It  remains  obscure  whether  the 
desmoplastic microenvironment plays a tumor-promoting 
or a tumor-suppressive role in colorectal cancer, and the 
literature is divided [9]. On one hand, the desmoplastic 
reaction  represents  an  effort  of  the  healthy  tissue  to 
entrap and encircle the tumor, by providing a biological 
limitation  to  the  expansion  of  cancer  cells.  However, 
cancer cells seem to adapt in this continuously modified 
desmoplastic landscape and develop alternative pathways 
to shift desmoplastic proteins towards their own favour 
[50,  51].  In  general,  the  host  responses  to  neoplastic 
lesions seem to represent a paradox. This is also evident in 
cancer-associated inflammation, whose primary role is to 
suppress cancer. However, it is now well-established that 
chronic inflammation in cancerous microenvironments is 
shifted towards promoting cancer progression [19, 31, 52]. 
By  utilizing  a  series  of  bioinformatic  tools, 
we  generated  and  partially  validated  a  proteomic 
myofibroblastic  signature  (Figure  4B)  with  potential 
functional  importance  in  the  regulation  of  colorectal 
cancer  metastasis.  The  smooth  muscle  enrichment 
analysis,  proposed  here  for  the  first  time,  unraveled 
markers of myofibroblastic differentiation. By focusing 
on several smooth muscle-like arrays in various gene-
expression  profile  databases,  we  selected  proteins 
Figure  8:  Proposed  model  for  the  expression  of  collagen  types  III  and  XII  at  the  CRC  desmoplastic  tumor 
microenvironment. The cartoon in the middle shows the tumor host cell interface; rounded cells represent cancer cells; spindle-shaped 
cells represent stromal cells. Colors show different cell subpopulations as depicted in legend. TC: tumor core cancer cells (grey, rounded); 
TIF: tumor invasion front cancer cells (red, rounded); TB: tumor budding cancer cells (orange, rounded); CAF: cancer-associated fibroblasts 
(blue, spindle-shaped); NF: normal fibroblasts (green, spindle-shaped). The gray double-edged arrows demonstrate where the expression 
of various markers (such as collagens) expands relatively to the tumor host cell interface.Oncotarget 2012; 3:  267-285 279 www.impactjournals.com/oncotarget
characterizing the myofibroblast proteome, since it is well-
demonstrated that CAFs deploy a full smooth muscle-like 
expression program. Notably, this strategy allowed us to 
re-identify previously-reported markers of myofibroblastic 
differentiation,  such  as  the  proteoglycan  versican 
(VCAN) isoforms V0 and V1 [53, 54], which validated 
our selection criteria. Interestingly, the myofibroblastic 
signature consisted of many desmoplastic proteins, e.g. 
constitutents of the ECM, as well as ECM-remodelling 
enzymes.  Indeed,  many  markers  of  myofibroblastic 
differentiation are proteins that are secreted by CAFs and 
deposited peritumorally (at the cancer invasion front) to 
form a desmoplastic film, as a reaction of the host tissue 
towards the invading cancer cells [9]. 
Collagen type XII was found in the myofibroblastic 
signature, but never reported before to be secreted by 
CAFs. Collagen type XII belongs to the fibril-associated 
collagens  with  interrupted  triple  helices  (FACITs), 
which are, in fact, fibrillar collagen organizers. Collagen 
type XII (as well as its relevant collagen type XIV) has 
one domain that anchors the molecule to the surface of 
another fibril (e.g. collagens type I and III), and three 
“finger-like”  domains  [55].  By  residing  in  collagen  I 
fibrils, collagen type XII participates in fibril structure 
interaction and organization, by further stabilizing them 
[56].  It  has  recently  been  reported  that  desmoplastic 
lesions  are  usually  characterized  by  non-organized 
collageneous  fibril  deposition  around  tumor  invasive 
cohorts, which significantly differs from normal collagen 
[57-59]. This loss of smooth collagen reorientation, and 
acquisition of a more disorganized one, called ‘cancer-
associated collagen’, is very characteristic during cancer 
development  [60,  61].  Therefore,  it  is  tempting  to 
speculate from our data that CAFs are recruited by cancer 
cells in an attempt to re-organize the cancer-associated 
collagen  in  desmoplastic  lesions  through  various 
mechanisms, including the secretion of collagen type XII. 
However, additional experiments are needed to unravel the 
regulation of its secretion, as well as its exact role in tumor 
progression.
Our  in vitro  experiments  revealed  that  collagen 
type  XII  was  abundantly  secreted  in  both  SW480Co 
and  SW620Co  cocultures,  but  we  could  not  discern 
which  cell  type  was  responsible  for  this  production. 
Immunohistochemical analysis revealed its expression by 
cancer cells lining the desmoplastic front and by cancer 
cells of the tumor budding subpopulation, in addition to 
CAFs. It is interesting that Collagen XII, in contrast to 
Collagen type III, was shown not to be just another stromal 
marker in our analysis. It is widely known that cancer cells 
progressively  lose  their  differentiation  upon  reaching 
the  tumor  invasion  front  area  and,  especially,  tumor 
budding [4, 6, 62]. These observations support the notion 
that collagen type XII might also be secreted by cells 
undergoing a dedifferentiation program, such as EMT, 
which is another reported mechanism of myofibroblastic 
induction [7]. Taken together, all these observations could 
contribute to a better understanding of the tumor-host cell 
interface in the CRC desmoplastic invasion front. Based 
on all these findings, we propose a schematic model of 
collagen expression at the desmoplastic invasion front in 
CRC metastasis (Figure 8).
METHODS
Antibodies
The following antibodies were purchased: mouse 
monoclonal  anti-CK  (cytokeratin  cocktail)  from  Cell 
Marque (clone A1E&AE3), mouse monoclonal anti-alpha-
SMA from DAKO (clone 1A4), mouse monoclonal anti-
collagen-III from Biogenex (clone HWD1.1; concentrated 
in  PBS),  mouse  monoclonal  anti-collagen-XII  from 
Sigma-Aldrich  (clone  1303).  Antibodies  against  the 
kallikreins 6 (KLK6), 7 (KLK7) and 10 (KLK10) were 
rabbit polyclonal, generated in our laboratory [63]. 
Cell culture
Cell lines 
The human SW480, SW620, HCT116 and HT29 
colon  cancer  and  CCD18Co  (18Co)  normal  colonic 
fibroblast cell lines were purchased from the American 
Type  Culture  Collection  (ATCC,  Rockville,  MD)  and 
were maintained in their favorable media, according to 
the  manufacturer’s  instructions. All  experiments  were 
performed within the first 10 passages from the initiation 
of all cultures. 
Stimulation experiments
For the preparation of conditioned media (CM) for 
stimulation  experiments,  18Co  cells  were  cultured  in 
T-175 flasks to ~75-80% confluency and then switched to 
serum-free medium (chemically defined Chinese hamster 
ovary – CDCHO) for 2 additional days. Then, CM were 
harvested  and  centrifuged  at  1,500  rpm  for  5  min  to 
remove cellular debris. CM were then concentrated 4 
times, using a 5 kDa molecular weight cutoff (Millipore 
Pellicon  XL)  and  rediluted  in  fresh  CDCHO  to  the 
initial volume. CM were filter-sterilized using a 0.22 μm 
membrane cut-off (Millipore) and kept at -20 ºC until used 
for stimulation experiments. All frozen CM were used 
within 15 days from their preparation. 
Development of cocultures
The  cell-contact  desmoplastic  cocultures 
SW480/18Co,  SW620/18Co,  HT29/18Co  and 
HCT116/18Co  were  termed  as  SW480Co,  SW620Co, 
HT29Co and HCT116Co, respectively. 18Co fibroblasts 
were initially seeded at T-175 flasks and allowed to reach Oncotarget 2012; 3:  267-285 280 www.impactjournals.com/oncotarget
at least 50% confluency in minimum essential medium 
(MEM),  supplemented  with  10%  fetal  bovine  serum 
(FBS). Then, flasks were rinsed with PBS to remove dead 
cells. Colon cancer cells (2X106) were resuspended in 
Dulbeco’s modified Eagle medium (DMEM) plus 10% 
FBS and placed on top of the pre-seeded 18Co cells. The 
cocultures were left to grow on DMEM 10% FBS for 
at least 2-3 additional days prior to further experiments. 
18Co cells showed excellent viability when cultured in 
either MEM or DMEM with 10% FBS, using a trypan blue 
assay (data not shown).
Proteomic analysis of CM
Sample preparation
All mono- and cocultures were washed with PBS 
and switched to CDCHO medium for 2 days. All CM 
were collected and normalized to a total of ~1.1 μg of 
total  protein  (Coomassie  colorimetric  assay;  Pierce 
biotechnology); samples were dialyzed, using a 3.5 kDa 
molecular  cut-off  membrane  (Spectrum  Laboratories, 
Inc., CA, USA), in 4 L of 1 mM ammonium bicarbonate 
solution (Fisher Scientific) (4 buffer changes). Dialyzed 
CM were frozen at -80 ºC and subjected to lyophylization 
until total dryness; samples were then denaturated by 
8  M  urea  (Fisher),  reduced  with  dichloro-diphenyl-
trichloroethane  (DDT)  (Sigma-Aldrich)  to  a  final 
concentration of 13 mM at 50 ºC for 30 min, alkylated 
with 500 mM iodoacetamide (Sigma-Aldrich) in the dark, 
at room temperature for 1 h, and finally desalted using a 
NAP5 column (GE Healthcare), using the manufacturer’s 
instructions. The 1 mL eluted samples were lyophilized 
and trypsin-digested (Promega) at a molar ratio of 1:50 
(trypsin:protein concentration) for 8 h. The peptides were 
again lyophilized to dryness and resuspended in 120 μL of 
0.26 M formic acid in 10% acetonitrile (mobile phase A). 
Strong cation exchange liquid chromatography (SCX-
LC) 
The  samples  were  fractionated  using  an Agilent 
high-performance  liquid  chromatography  (HPLC) 
system connected to a PolySULFOETHYL ATM column 
with 200-Å pore size and a diameter of 5 μm (The Nest 
Group Inc.). A 1-h linear gradient was used with 1 mol/L 
ammonium formate and 0.26 mol/L formic acid in 10% 
acetonitrile (mobile phase B) at a flow rate of 200 μL/
min. Fractions were collected every 5 min for the first 
20 min of the run and every 2 min for the following 40 
min, to a total number of 24 fractions/replicate. Of these, 
16 fractions, corresponding to the highest concentration 
of eluted peptides, were kept for mass spectrometry. A 
peptide cation exchange standard (Bio-Rad), consisting of 
four peptides, was run at the beginning of each replicate to 
assess column performance. 
Reverse phase liquid chromatography (RP-LC)
HPLC  fractions  were  C18-extracted  using  a 
ZipTipC18 pipette tip (Millipore) and eluted in 5 μL of 
90% acetonitrile, 0.1% formic acid, 10% water and 0.02% 
trifluoroacetic acid (Buffer B). 80 μL of 95% water, 0.1% 
formic acid, 5% acetonitrile and 0.02% trifluoroacetic 
acid (Buffer A) were added to this mixture, and 40 μL 
were injected via an autosampler on an Agilent HPLC. 
The peptides were first separated onto a 2-cm C18 guard 
column  (inner  diameter  200μm),  then  eluted  onto  a 
resolving 5-cm analytical C18 column (inner diameter 75 
μm) with an 8-μm tip (New Objective). 
Tandem mass spectrometry (MS/MS)
This  HPLC  system  was  coupled  online  to  an 
LTQ-Orbitrap  XL  (Thermo  Fisher  Scientific)  mass 
spectrometer, using nano-electrospray ionization (ESI) 
source (Proxeon Biosystems), in data-dependent mode. 
Each fraction was run with a 55-min gradient and eluted 
peptides were subjected to one full MS scan (450-1450 
m/z) in the Orbitrap at 60,000 resolution, followed by six 
data-dependent MS/MS scans in the linear ion trap (LTQ 
Orbitrap). Unassigned charge states and charges 1+ and 
4+ were all ignored, as depicted through the charge-state 
screening and preview mode. 
Protein identification
Data files were created by use of Mascot Daemon 
(version  2.2.0)  and  extract_msn.  The  resulting  mass 
spectra from each fraction were analyzed using Mascot 
(Matrix  Science;  version  2.2)  and  X!Tandem  (Global 
Proteome Machine Manager; version 2005.06.01) search 
engines,  using  the  International  Protein  Index  human 
database  (version  3.62,  167,894  protein  sequences), 
which  includes  both  forward  and  reverse  sequences. 
The resulting Mascot and X!Tandem files were loaded 
into Scaffold (Proteome Software; version 2.6) to cross 
validate the data files from both engines. Detection of a 
minimum of two unique peptides was required to accept 
positive protein identification. A normalized method for 
spectral counting analysis was used and spectrum reports 
were exported from Scaffold and uploaded into an in-
house  developed  database  (http://www.acdc-proteome.
info/) for further analysis. This database provides the tools 
to compare protein datasets and generate Venn diagrams 
from proteomic experiments.
Bioinformatic analysis
Selection of secretome proteins
Individual proteins were subjected to prediction of 
protein secretory pathway with the presence of signal 
peptide  (classical  secretory  mechanism)  (SignalP  3.0) 
(http://www.cbs.dtu.dk/services/SignalP/)  [64,  65]  and 
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secretory  mechanism)  (SecretomeP  2.0)  (http://www.
cbs.dtu.dk/services/SecretomeP) [66] and for presence of 
amino acid sequences that correspond to transmembrane 
helices (TMHMM 2.0) (http://www.cbs.dtu.dk/services/
TMHMM)  [67].  The  sequential  use  of  the  above-
mentioned tools on a given proteomic dataset, is termed 
“secretome algorithm”.
Smooth muscle enrichment analysis
Two  publicly-available  gene  expression  meta-
analysis databases were utilized to examine the tissue 
and cell type expression patterns of individual proteins 
of interest. These databases (Genevestigator and bioGPS) 
allow the user to study gene expression patterns from 
multiple  microarray  experiments.  Since  we  wished  to 
define smooth muscle-like and/or -specific proteins as 
potential myofibroblastic markers of CAFs, we termed 
this gene expression meta-analysis, as “smooth muscle 
enrichment analysis”. For Genevestigator (https://www.
genevestigator.com/) [68], only probes (1-3 per protein) 
with high probability to correspond to the actual gene of 
interest were searched for their tissue expression profiles. 
For some proteins, no such probes were found, and these 
were excluded from the meta-analysis. A heatmap showing 
expression of these genes in various human, primary, 
normal and cancer cell lines was constructed based on 
microarray  data  from  both  gene  expression  omnibus 
(GEO) (5146 microarray experiments) and ArrayExpress 
(54 microarray experiments) array sources. Genevestigator 
was set to automatically accept high quality control arrays 
in the meta-analysis. We observed that the normal cell line 
arrays, in Genevestigator, included four smooth muscle-
like cell types: bronchial smooth muscle cell, coronary 
smooth muscle cell, aortic vascular smooth muscle cell 
and hepatic myofibroblast. Although none of these arrays 
actually corresponds to colonic tissues and no colonic 
myofibroblast  arrays  currently  exist  in  any  database, 
we accepted the notion that these 4 array types could 
be representative of any smooth muscle-like tissue, if 
the gene expression pattern was reproducible. Thus, we 
accepted as “smooth muscle-like proteins”, only those 
that had high expression levels in at least three out of 
these four representative arrays, in the Genevestigator 
database. To achieve higher confidence of smooth muscle-
like and/or -specific proteins, we integrated expressional 
data from Genevestigator with the bioGPS database. In 
the latter database, we accepted proteins that did not have 
a wide expression pattern; thus we accepted only those 
with significant expression in less than 5 of the bioGPS 
reported tissues, compared to the background expression 
levels. In addition, we accepted only those proteins whose 
expression  in  the  “smooth  muscle  tissue”  arrays  was 
amongst the 3 highest expressions in all bioGPS arrays.
Tissue specificity
We investigated the tissue specificity of individual 
gene probes of interest with Gene Enrichment Profiler 
(http://xavierlab2.mgh.harvard.edu/EnrichmentProfiler/), 
containing 126 human primary tissues represented by 557 
microarray experiments. Enrichment graphs were exported 
directly from the application.
Immunocytochemistry
18Co  cells  were  plated  on  poly-L-lysine-
coated  coverslips  (POLY-PREP  SLIDES,  Sigma)  at 
approximately  30,000  cells/coverslip,  in  MEM,  10% 
FBS, and were left for 24 h in Petri dishes to allow for 
adherence and flattening. Once the fibroblasts adhered, 
the  coverslips  were  washed  with  phosphate  buffered 
saline  (PBS).  SW480  and  SW620  cells  were  plated 
on top of the fibroblasts at approximately 20,000 cells/
coverslip, in DMEM, 10% FBS and were left for 32 h 
to allow for adherence and proliferation. Then, the slides 
were washed with PBS and left for an additional 72 h, 
in  CDCHO,  to  allow  growth  and  paracrine  signaling. 
Replicates of monocultured cells, served as controls. After 
the termination of cocultures, all slides were washed with 
PBS, fixed in 4% paraformaldehyde for 1 h and soaked 
in  ethanol  overnight.  The  cells  were  permeabilized, 
using 2 mL of 0.05% Triton-X-100 detergent for 5 min. 
Cells were washed with PBS and covered with 0.5 mL 
peroxidase blocking reagent for 5 min. Cells were again 
washed with PBS and subsequently incubated for 1.5 h 
at  room  temperature  with  primary  antibody,  directed 
against α-SMA, diluted 1:50 in PBS. Cells were then 
washed with PBS and incubated with 0.5 mL goat serum 
blocking agent for 15 min. cells were washed again with 
PBS and incubated with peroxidase-conjugated secondary 
antibody, diluted 1:200, in PBS. Cells were washed again 
with PBS and incubated with 0.2 mL DAB chromogen 
buffer and counterstained with hematoxylin, following 
routine staining procedures. Replicates of no-antibody 
controls were also included. Fluorescence was visualized 
using light microscopy (Olympus), attached to a Q-Color3 
camera (Olympus) and Q-Capture Pro image analysis 
software.
Immunohistochemistry
Enrolled  were  paraffin  tissue  sections  from  15 
archived  cases  of  moderately  or  poorly  differentiated 
human  CRC,  showing  an  intense  desmoplastic 
reaction  in  invasive  areas.  The  immunohistochemical 
staining  was  performed  using  the  Bond  automated 
immunohistochemistry  system  (Bondmax,  Leica 
Microsystems, UK)-pretreatment with epitope retrieval 
(pH  8).  The  following  mouse  monoclonal  antibodies 
were used; against Cytokeratin cocktail (Cell Marque, 
clone A1E&AE3, 1:70), alpha-SMA (DAKO, clone 1A4, 
1:100), Collagen III (Biogenex, clone HWD1, 1:100) and 
Collagen XII (Sigma-Aldrich, clone 1303, 1:30).Oncotarget 2012; 3:  267-285 282 www.impactjournals.com/oncotarget
In-vitro functional assays
Cell proliferation (crystal violet) assay
Cancer cells (SW480, SW620) were plated in 24-
well plates at low confluency (~25%) and left for 24 h 
in DMEM 10% FBS to allow for adherence. Then, all 
wells were washed with PBS and specific experimental 
conditions were applied in each well. After the termination 
of  the  experiment,  all  CM  were  removed,  cells  were 
washed  with  PBS  and  subsequently  fixed  with  10% 
formalin  for  20  minutes. After  fixation,  crystal  violet 
solution  (0.05%)  was  applied  in  the  wells  (~1  mL) 
for 30 minutes. For quantitative assessment, 1 mL of 
100% methanol was added in each well to solubilize the 
absorbed crystal violet dye, plates were gently shaken for 
3 minutes and absorbance was measured at 540 nm. Data 
were graphed as relative mean absorbance from a total of 
six replicates per condition.
Cell migration (scratch) assay
Cancer cells were seeded at six-well plates. After 
forming confluent monolayers, a pipette tip was used to 
create a single straight scratch on the well and they were 
rinsed 3 times with 4-5 mL of PBS to remove detached 
and dead cells. After washing, the experimental conditions 
and treatments were applied in the wells, in at least 3 
biological replicates. The wells were left for 36 hours then 
all media were removed, cells were washed once with 
PBS and fixed with 10% formalin for 20 minutes. Cells 
were washed twice with PBS and examined under light 
microscopy.
Cell adhesion assay
Our  preliminary  observations  show  that  SW480/
SW620  cells  are  not  able  to  strongly  adhere  in  cell 
culture plates without FBS; however, if these cells are 
already attached, a subsequent serum deprivation does 
not cause detachment, even if it persists for 6-7 days 
(data not shown). Based on this, we developed a simple 
cell  adhesion  assay  setup.  SW480/SW620  cells  were 
resuspended in serum-free medium, and reseeded in 24-
well plates. Then, various experimental conditions were 
applied in the wells; in some cases, plates have already 
been pre-seeded with 18Co fibroblasts (20% confluency) 
and in other cases only 18Co medium was used as a 
supplement  in  the  wells.  Untreated  wells  served  as 
controls. Adhesion of cancer cells on the plate surface or 
pre-seeded fibroblasts was estimated after 48 hours, using 
light microscopy.
Resistance to chemotherapy assay
SW480/SW620  cells  were  seeded  at  5,000/well 
in 96-well plates and left for 24 hours to adhere and 
proliferate  in  DMEM,  supplemented  with  10%  FBS. 
Then, wells were switched to CDCHO medium and were 
treated with 5-fluororacil (5-FU) antineoplastic agent in a 
dose-response manner. For each concentration of the drug, 
cells were either treated additionally with 18Co or placebo 
CM. Cells were left for 48 hours to investigate whether 
the 18Co CM would cause a pharmacological rescue to 
the drug treatment. The evaluation of cell viability at the 
termination of the assay was done with the Alamar Blue 
assay. Specifically, all wells were washed with PBS and 
Alamar Blue (100 μL of 10% v/v in PBS solution) was 
added in each well. The reagent was left for 3-4 hours 
and then fluorescence was measured with fluorescence 
spectrophotometer using 560 EX nm/590 EM nm filter 
setting. Alamar blue is a stable, soluble, non-toxic agent 
that monitors the innate metabolic activity of the cells. The 
assay is based on an oxidation-reduction indicator, directly 
proportional to metabolic activity, thus “translating” the 
fluorescence signal into viability signal.
ELISA
The concentration of KLK6, KLK7 and KLK10 in 
mono- and coculture supernatants, was determined by 
in-house  developed  sandwich-type  immunoassays,  as 
previously described [63]. Concentration was determined 
by interpolation from a standard curve, using recombinant 
proteins,  as  standards.  The  concentrations  of  MMP2 
and  urokinase-type  plasminogen  activator  (uPA)  were 
measured  with  commercially  available  immunoassays 
(Invitrogen).
Quantitative PCR
For clinical validation, the TissueScan Colon Cancer 
cDNA Array III was used (Origene). Quantitative PCR 
was conducted on these samples using 1X SYBR green 
reagent  (Applied  Biosystems)  and  transcript  levels  of 
beta-actin and COL12A1 were measured on a 7500 ABI 
System. The following forward (F) and reverse (R) primer 
sequences were used: 
B-actin F 5’- CACCATTGGCAATGAGCGGTTC-3’
B-actin R 5’- AGGTCTTTGCGGATGTCCACGT-3’ 
COL12A1F5’- GTGCCTGTAGTCAGCCTGAA-3’ 
COL12A1R5’- GTCTTGTTGGCTCTGTGTCCT-3’
Statistical analysis
All  graphs  are  presented  with  mean  values  and 
standard deviations calculated from biological replicates. 
Statistical significance was examined by student’s t-test 
and  p<0.05  was  considered  significant. The  statistical 
software EpiInfo version 7.0.8.0 was used.
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